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Background: Controversy persists regarding the efficacy of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers 
(ARBs) in the prevention of recurrent atrial fibrillation. We performed a meta-analysis of randomized controlled trials (RCTs) to evaluate the efficacy 
of ACEIs and ARBs in the prevention of recurrent atrial fibrillation.
Methods: A systematic literature search for RCTs, using ACEIs or ARBs and providing data on the outcome of recurrent atrial fibrillation, revealed 8 
studies including 2,323 patients. The Mantel-Haenszel random-effect model was used to calculate relative risk (RR) for studies using ACEIs or ARBS 
and, also for studies using ARBs. The Fixed-effect model was used to calculate RR for studies using ACEIs. A two-sided alpha error of less than 0.05 
was considered to be statistically significant (p<0.05).
Results: Meta-analysis of the studies (figure below) revealed that ACEIs or ARBs significantly reduced the incidence of recurrent atrial fibrillation 
(RR, 0.611; 95% CI, 0.441 to 0.847; p = 0.003). The RR for recurrent atrial fibrillation was 0.643 (95% CI, 0.439 to 0.941; p = 0.023) for studies 
using ARBs and 0.54 (95% CI, 0.377 to 0.80; p = 0.002) for studies using ACEIs.
Conclusions: Angiotensin blockade, with either angiotensin converting enzyme inhibitors or angiotensin receptor blockers, was associated with a 
significant reduction in the incidence of recurrent atrial fibrillation.
